Unnamed: 0,title,date,stock,sentiment
1329945.0,"H.C. Wainwright Reiterates Buy on Verastem, Raises Price Target to $3",2020-05-11 07:25:00-04:00,VSTM,neutral
1329946.0,"Verastem Oncology Q4 EPS $(0.400) Beats $(0.450) Estimate, Sales $3.617M Miss $4.500M Estimate",2020-05-07 16:51:00-04:00,VSTM,negative
1329947.0,Traders Circulate May 4-Dated ClinicalTrials.gov Trial Record For Verastem's Duvelisib To Combat Coronavirus; Recruitment Status Shows 'Not Yet Recruiting',2020-05-04 08:32:00-04:00,VSTM,negative
1329948.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,VSTM,neutral
1329949.0,82 Biggest Movers From Yesterday,2020-04-29 04:30:00-04:00,VSTM,neutral
1329950.0,56 Stocks Moving In Tuesday's Mid-Day Session,2020-04-28 12:27:00-04:00,VSTM,neutral
1329951.0,Verastem Option Alert: Jun 19 $3 Calls Sweep (2) near the Ask: 475 @ $0.25 vs 11420 OI; Earnings 5/11 After Close [est] Ref=$2.085,2020-04-28 09:42:00-04:00,VSTM,positive
1329952.0,96 Biggest Movers From Yesterday,2020-04-28 04:22:00-04:00,VSTM,neutral
1329953.0,Mid-Afternoon Market Update: Dow Surges 350 Points; CNX Midstream Partners Shares Plummet,2020-04-27 14:42:00-04:00,VSTM,positive
1329954.0,Verastem Files Prospectus Related To Resale Or Other Disposition Of Up To 46.5M Shares Of Common Stock By Selling Shareholders,2020-04-27 13:47:00-04:00,VSTM,positive
1329955.0,72 Stocks Moving In Monday's Mid-Day Session,2020-04-27 12:34:00-04:00,VSTM,neutral
1329956.0,Mid-Day Market Update: Crude Oil Slides 28%; Avadel Pharmaceuticals Shares Climb,2020-04-27 12:29:00-04:00,VSTM,negative
1329957.0,P/E Ratio Insights for Verastem,2020-04-27 11:15:00-04:00,VSTM,neutral
1329958.0,Morning Market Stats in 5 Minutes,2020-04-27 10:33:00-04:00,VSTM,neutral
1329959.0,Mid-Morning Market Update: Markets Open Higher; Deutsche Bank Projects To Report Strong Q1 Results,2020-04-27 10:18:00-04:00,VSTM,positive
1329960.0,Verastem shares are trading lower after the company provided response rate data from its phase 1 study of VS-6766 in mutant tumors.,2020-04-27 08:01:00-04:00,VSTM,neutral
1329961.0,33 Stocks Moving in Monday's Pre-Market Session,2020-04-27 07:36:00-04:00,VSTM,neutral
1329962.0,Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at AACR 2020 Virtual Annual Meeting I,2020-04-27 05:42:00-04:00,VSTM,neutral
1329963.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,VSTM,negative
1329964.0,"The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures $54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO",2020-04-24 08:38:00-04:00,VSTM,positive
1329965.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-23 10:41:00-04:00,VSTM,neutral
1329966.0,"The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt",2020-04-23 07:53:00-04:00,VSTM,negative
1329967.0,Shares of several healthcare companies are trading higher as equities gain amid oil prices potentially stabilizing following the recent crash.,2020-04-22 12:03:00-04:00,VSTM,positive
1329968.0,"The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives",2020-04-21 08:19:00-04:00,VSTM,positive
1329969.0,78 Biggest Movers From Yesterday,2020-04-21 04:32:00-04:00,VSTM,neutral
1329970.0,54 Stocks Moving In Monday's Mid-Day Session,2020-04-20 12:43:00-04:00,VSTM,neutral
1329971.0,Stocks That Hit 52-Week Highs On Monday,2020-04-20 10:25:00-04:00,VSTM,neutral
1329972.0,Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-07 07:48:00-04:00,VSTM,positive
1329973.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several U.S. hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 11:47:00-04:00,VSTM,positive
1329974.0,"Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.",2020-03-16 10:50:00-04:00,VSTM,negative
1329975.0,"H.C. Wainwright Maintains Buy on Verastem, Raises Price Target to $2.75",2020-03-16 07:26:00-04:00,VSTM,neutral
1329976.0,90 Biggest Movers From Yesterday,2020-03-12 06:10:00-04:00,VSTM,neutral
1329977.0,Verastem Oncology Expects Its R&D and SG&A Expenses For FY20 To Be In The Range Of $70M - $85M,2020-03-11 16:13:00-04:00,VSTM,neutral
1329978.0,"Verastem Oncology Q4 EPS $(0.51) Down From $(0.37) YoY, Sales $3.617M Up From $1.21M YoY",2020-03-11 16:11:00-04:00,VSTM,neutral
1329979.0,78 Stocks Moving In Wednesday's Mid-Day Session,2020-03-11 12:12:00-04:00,VSTM,neutral
1329980.0,52 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-09 08:04:00-04:00,VSTM,neutral
1329981.0,100 Biggest Movers From Friday,2020-03-09 05:25:00-04:00,VSTM,neutral
1329982.0,40 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-03-03 08:10:00-05:00,VSTM,neutral
1329983.0,"Cantor Fitzgerald Maintains Overweight on Verastem, Raises Price Target to $6",2020-03-03 06:40:00-05:00,VSTM,negative
1329984.0,140 Biggest Movers From Friday,2020-03-02 04:43:00-05:00,VSTM,neutral
1329985.0,86 Stocks Moving In Friday's Mid-Day Session,2020-02-28 12:19:00-05:00,VSTM,negative
1329986.0,Verastem Oncology shares are trading higher after the company announced a strategic direction to accelerate the development of CH5126766 for the treatment of KRAS mutant solid tumors.,2020-02-28 09:14:00-05:00,VSTM,positive
1329987.0,50 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-02-28 08:34:00-05:00,VSTM,neutral
1329988.0,"Verastem Sees FY20 R&D, SG&A Expenses $70M-$85M",2020-02-28 06:08:00-05:00,VSTM,neutral
1329989.0,"Verastem Highlights New Strategic Direction: Will Accelerate Development Of VS-6766, Defactinib Combo, Duvelisib, Focus On Commercial Activities For COPIKTRA",2020-02-28 06:07:00-05:00,VSTM,neutral
1329990.0,Verastem Reports $100M Private Placement Of Common Stock To Premier Life Sciences Investors,2020-02-28 06:03:00-05:00,VSTM,neutral
1329991.0,Verastem shares are trading higher after Point72 reported a 7.4% passive stake in the company.,2020-02-04 11:33:00-05:00,VSTM,positive
1329992.0,Point72 Reports 7.4% Passive Stake In Verastem,2020-02-03 16:29:00-05:00,VSTM,positive
1329993.0,Verastem Oncology Announces Dosing Of First Patient In CSPC's Chinese Study Evaluating COPIKTRA In Patients With Relapsed Or Refractory Follicular Lymphoma,2020-01-29 07:25:00-05:00,VSTM,neutral
1329994.0,Verastem Oncology Announces Dosing of First Patient in CSPC's Chinese Study Evaluating COPIKTRA in Patients with Relapsed or Refractory Follicular Lymphoma,2020-01-29 07:16:00-05:00,VSTM,neutral
1329995.0,15 Biotechnology Stocks Moving In Thursday's After-Market Session,2020-01-23 23:28:00-05:00,VSTM,neutral
1329996.0,20 Healthcare Stocks Moving In Thursday's After-Market Session,2020-01-23 23:13:00-05:00,VSTM,neutral
1329997.0,50 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-08 08:31:00-05:00,VSTM,neutral
1329998.0,"The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results",2020-01-08 08:12:00-05:00,VSTM,positive
1329999.0,Verastem Oncology shares are trading higher after the company announced a global licensing agreement with Chugai Pharmaceutical to develop and commercialize RAF/MEK Inhibitor CH5126766.,2020-01-08 07:37:00-05:00,VSTM,positive
1330000.0,"Verastem Oncology Announces Global Licensing Agreement With Chugai Pharmaceutical Co., Ltd. To Develop And Commercialize RAF/MEK Inhibitor CH5126766; Co. To Make $3M Upfront Payment To Chugai And Pay Royalties",2020-01-08 07:03:00-05:00,VSTM,positive
1330001.0,30 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-18 08:11:00-05:00,VSTM,neutral
1330002.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-09 08:26:00-05:00,VSTM,neutral
1330003.0,Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting,2019-12-07 14:31:00-05:00,VSTM,neutral
1330004.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,VSTM,neutral
1330005.0,Verastem Oncology shares are trading higher. Not seeing any news to justify the price action. NOTE: The stock is trading on above-average volume.,2019-11-26 10:23:00-05:00,VSTM,positive
1330006.0,Verastem Reports Submission Of Marketing Authorization Application To EMA For COPIKTRA,2019-11-25 07:03:00-05:00,VSTM,neutral
1330007.0,Verastem Shares Spike ~20% As Traders Circulate Word Of New Buy Recommendation By Unknown Newsletter,2019-11-22 10:56:00-05:00,VSTM,positive
1330008.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,VSTM,neutral
1330009.0,Stocks That Hit 52-Week Lows On Monday,2019-11-18 13:49:00-05:00,VSTM,negative
1330010.0,Stocks That Hit 52-Week Lows On Friday,2019-11-15 10:43:00-05:00,VSTM,negative
1330011.0,"The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval",2019-11-15 07:08:00-05:00,VSTM,negative
1330012.0,Stocks That Hit 52-Week Lows On Thursday,2019-11-14 11:11:00-05:00,VSTM,negative
1330013.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,VSTM,positive
1330014.0,Stocks That Hit 52-Week Lows On Wednesday,2019-11-13 10:50:00-05:00,VSTM,negative
1330015.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,VSTM,neutral
1330016.0,Stocks That Hit 52-Week Lows On Tuesday,2019-11-12 10:52:00-05:00,VSTM,negative
1330017.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,VSTM,negative
1330018.0,"Verastem Reaffirms FY19 Guidance, Sees COPIKTRA Sales $12M-$14M",2019-10-29 16:25:00-04:00,VSTM,neutral
1330019.0,"Verastem Oncology Q3 Adj. EPS $(0.35) Beats $(0.46) Estimate, Sales $9.03M Beat $8.95M Estimate",2019-10-29 16:24:00-04:00,VSTM,neutral
1330020.0,"The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study",2019-10-29 07:32:00-04:00,VSTM,positive
1330021.0,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-23 08:48:00-04:00,VSTM,neutral
1330022.0,Verastem Oncology Highlights COPIKTRA Presentations At Lymphoma & Myeloma 2019 Int'l. Congress,2019-10-23 07:17:00-04:00,VSTM,neutral
1330023.0,"The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings",2019-10-15 07:50:00-04:00,VSTM,positive
1330024.0,Stocks That Hit 52-Week Lows On Monday,2019-10-14 11:14:00-04:00,VSTM,negative
1330025.0,5 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-10-10 08:11:00-04:00,VSTM,neutral
1330026.0,Verastem Oncology Doses its First Patient in Yakult Honsha's Study Evaluating COPIKTRA,2019-10-07 07:12:00-04:00,VSTM,neutral
1330027.0,Verastem Oncology Receives Orphan Drug Designation From FDA For COPIKTRA For The Treatment Of T-Cell Lymphoma,2019-10-03 14:30:00-04:00,VSTM,neutral
1330028.0,"The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo",2019-10-03 07:34:00-04:00,VSTM,negative
1330029.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,VSTM,negative
1330030.0,25 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-08 08:35:00-04:00,VSTM,neutral
1330031.0,Verastem Oncology shares are trading lower after the company reported worse-than-expected Q2 EPS results.,2019-08-02 14:19:00-04:00,VSTM,neutral
1330032.0,"Verastem Oncology Q2 EPS $(0.57) Misses $(0.5) Estimate, Sales $3M Beat $2.32M Estimate",2019-08-01 16:16:00-04:00,VSTM,negative
1330033.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,VSTM,negative
1330034.0,28 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-01 04:20:00-04:00,VSTM,neutral
1330035.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,VSTM,positive
1330036.0,30 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-29 09:35:00-04:00,VSTM,neutral
1330037.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,VSTM,neutral
1330038.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,VSTM,negative
1330039.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-07-26 10:09:00-04:00,VSTM,neutral
1330040.0,"Verastem Oncology shares are trading higher after the company signed an exclusive license agreement with Sanofi for the development and commercialization of COPIKTRA in Russia and CIS, Turkey, the Middle East and Africa.",2019-07-26 09:39:00-04:00,VSTM,positive
1330041.0,"The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint",2019-07-26 07:26:00-04:00,VSTM,neutral
1330042.0,30 Healthcare Stocks Moving In Thursday's After-Market Session,2019-07-26 04:36:00-04:00,VSTM,neutral
1330043.0,"Verastem Oncology Signs An Exclusive License Agreement With Sanofi For The Development And Commercialization Of COPIKTRA In Russia And CIS, Turkey, The Middle East And Africa; Co. To Receive $5M Upfront, Up To $42M In Milestones",2019-07-25 16:46:00-04:00,VSTM,positive
1330044.0,68 Biggest Movers From Friday,2019-06-24 04:25:00-04:00,VSTM,neutral
1330045.0,44 Stocks Moving In Friday's Mid-Day Session,2019-06-21 12:13:00-04:00,VSTM,neutral
1330046.0,Verastem Shares Response Rate From COPIKTRA Data,2019-06-21 09:01:00-04:00,VSTM,positive
1330047.0,26 Stocks Moving In Friday's Pre-Market Session,2019-06-21 08:34:00-04:00,VSTM,neutral
1330048.0,"UPDATE: Verastem Says Data From Two Phase 1 Studies Show Response Rates Of 44-57%, Including Complete Response Rates Of 15-22%",2019-06-21 07:02:00-04:00,VSTM,neutral
1330049.0,Verastem Oncology Highlights Presentation Of COPIKTRA Data In Peripheral T-Cell Lymphoma At 2019 International Conference On Malignant Lymphoma,2019-06-21 07:02:00-04:00,VSTM,neutral
1330050.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,VSTM,positive
1330051.0,Verastem Oncology Presents COPIKTRA Data at the European Hematology Association 2019 Annual Meeting,2019-06-17 07:21:00-04:00,VSTM,neutral
1330052.0,Verastem Oncology Highlights Will Present New COPIKTRA™ Dose Modification Data from Patients Treated in the Phase 3 DUO Study At ASCO,2019-05-15 17:17:00-04:00,VSTM,neutral
1330053.0,Verastem Oncology shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results; Raymond James also downgraded the company's stock from Outperform to Market Perform.,2019-05-10 10:33:00-04:00,VSTM,neutral
1330054.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,VSTM,negative
1330055.0,"Raymond James Downgrades Verastem, Inc. - Common Stock to Market Perform",2019-05-10 06:59:00-04:00,VSTM,neutral
1330056.0,Verastem Oncology shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.,2019-05-09 17:05:00-04:00,VSTM,neutral
1330057.0,"Verastem Q1 EPS $(0.52) Misses $(0.47) Estimate, Sales $1.671M Miss $2.91M Estimate",2019-05-09 16:43:00-04:00,VSTM,negative
1330058.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,VSTM,neutral
1330059.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,VSTM,negative
1330060.0,"The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen",2019-05-03 07:49:00-04:00,VSTM,positive
1330061.0,"The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio",2019-04-18 07:42:00-04:00,VSTM,neutral
1330062.0,"The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives",2019-04-16 08:10:00-04:00,VSTM,neutral
1330063.0,44 Biggest Movers From Yesterday,2019-04-16 05:44:00-04:00,VSTM,neutral
1330064.0,"Benzinga's Top Upgrades, Downgrades For April 3, 2019",2019-04-03 09:16:00-04:00,VSTM,positive
1330065.0,"Cantor Fitzgerald Initiates Coverage On Verastem Oncology with Overweight Rating, Announces $5 Price Target",2019-04-03 07:29:00-04:00,VSTM,negative
1330066.0,Verastem Oncology To Present At H.C. Wainwright Global Life Sciences Conference,2019-04-02 07:18:00-04:00,VSTM,neutral
1330067.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-03-13 12:41:00-04:00,VSTM,neutral
1330068.0,Verastem Oncology shares are trading lower after the company reported worse-than-expected Q4 sales.,2019-03-13 09:33:00-04:00,VSTM,neutral
1330069.0,40 Stocks Moving In Wednesday's Pre-Market Session,2019-03-13 08:10:00-04:00,VSTM,neutral
1330070.0,"The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie",2019-03-13 07:27:00-04:00,VSTM,negative
1330071.0,Verastem Oncology shares are trading lower after the company reported lower-than-expected Q4 sales results.,2019-03-12 16:28:00-04:00,VSTM,neutral
1330072.0,"Verastem Q4 EPS $(0.37) Beats $(0.53) Estimate, Sales $1.21M Miss $2.92M Estimate",2019-03-12 16:26:00-04:00,VSTM,negative
1330073.0,"The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug",2019-03-12 07:47:00-04:00,VSTM,positive
1330074.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs",2019-03-10 14:32:00-04:00,VSTM,neutral
1330075.0,Verastem Oncology Highlights Presentation Of COPIKTRA (Duvelisib) Data At The 23rd Annual International Congress On Hematologic Malignancies,2019-03-07 17:02:00-05:00,VSTM,neutral
1330076.0,Verastem Oncology Highlights Publication Of Phase 2 DYNAMO Study Results In Indolent Non-Hodgkin Lymphoma In The Journal Of Clinical Oncology,2019-02-14 07:53:00-05:00,VSTM,neutral
1330077.0,44 Biggest Movers From Friday,2019-01-14 04:46:00-05:00,VSTM,neutral
1330078.0,22 Stocks Moving In Wednesday's Pre-Market Session,2019-01-09 08:02:00-05:00,VSTM,neutral
1330079.0,"The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO",2019-01-04 07:59:00-05:00,VSTM,positive
1330080.0,Verastem Oncology Outlines Strategic Priorities For 2019,2019-01-03 16:07:00-05:00,VSTM,neutral
1330081.0,Verastem Shareholders Approve Amendment Too Increase Number Of Authorized Common Shares From 100M To 200M Shares,2018-12-20 16:27:00-05:00,VSTM,positive
1330082.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,VSTM,neutral
1330083.0,"The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering",2018-11-08 08:10:00-05:00,VSTM,negative
1330084.0,88 Biggest Movers From Yesterday,2018-11-08 04:54:00-05:00,VSTM,neutral
1330085.0,"Verastem, Inc. Q3 EPS $(0.29) Beats $(0.42) Estimate, Sales $15.508M",2018-11-07 17:27:00-05:00,VSTM,neutral
1330086.0,Verastem Oncology Announces Collaboration With The Leukemia & Lymphoma Society To Accelerate Development Of Duvelisib For Peripheral T-Cell Lymphoma,2018-11-07 07:25:00-05:00,VSTM,neutral
1330087.0,44 Biggest Movers From Yesterday,2018-10-15 05:06:00-04:00,VSTM,neutral
1330088.0,41 Stocks Moving In Friday's Mid-Day Session,2018-10-12 13:42:00-04:00,VSTM,neutral
1330089.0,Verastem Oncology's COPIKTRA Capsules Added to the National Comprehensive Cancer Network's Clinical Practice Guidelines in Oncology,2018-10-08 07:06:00-04:00,VSTM,negative
1330090.0,36 Stocks Moving In Friday's Mid-Day Session,2018-10-05 12:37:00-04:00,VSTM,neutral
1330091.0,23 Stocks Moving In Friday's Pre-Market Session,2018-10-05 08:09:00-04:00,VSTM,neutral
1330092.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-10-02 13:51:00-04:00,VSTM,neutral
1330093.0,24 Stocks Moving In Tuesday's Pre-Market Session,2018-10-02 08:05:00-04:00,VSTM,neutral
1330094.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-09-27 12:37:00-04:00,VSTM,neutral
1330095.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2018-09-26 16:41:00-04:00,VSTM,neutral
1330096.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-09-26 12:32:00-04:00,VSTM,neutral
1330097.0,"The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial",2018-09-26 08:25:00-04:00,VSTM,positive
1330098.0,28 Stocks Moving In Wednesday's Pre-Market Session,2018-09-26 08:03:00-04:00,VSTM,neutral
1330099.0,51 Biggest Movers From Yesterday,2018-09-26 05:17:00-04:00,VSTM,neutral
1330100.0,6 Stocks Moving In Tuesday's After-Hours Session,2018-09-25 17:08:00-04:00,VSTM,neutral
1330101.0,Verastem shares are up 7.8% after the company signed an exclusive license agreement with CSPC Pharmaceutical Group for the development and commercialization of COPIKTRA in China.,2018-09-25 16:57:00-04:00,VSTM,positive
1330102.0,"Verastem Oncology Signs Exclusive License Agreement For Development And Commercialization Of COPIKTRA (duvelisib) In China; Veristem Will Receive Upfront Payment Of $15M, Will Be Eligible For Up To $30M In Milestones",2018-09-25 16:21:00-04:00,VSTM,positive
1330103.0,41 Stocks Moving In Tuesday's Mid-Day Session,2018-09-25 13:06:00-04:00,VSTM,neutral
1330104.0,Verastem In 8-K Says Says COPIKTRA Will Be Available In US Market Immediately,2018-09-24 17:05:00-04:00,VSTM,neutral
1330105.0,"Verastem Shares Resume Trade, Up 7%",2018-09-24 16:20:00-04:00,VSTM,positive
1330106.0,Verastem Shares To Resume Trade At 4:20 p.m. EDT,2018-09-24 16:04:00-04:00,VSTM,positive
1330107.0,Verastem Reports FDA Approval Of COPIKTRA Capsules,2018-09-24 15:48:00-04:00,VSTM,positive
1330108.0,Watching Shares Of Verastem As Document On FDA Site Appears To Highlight Approval For COPIKTRA (duvelisib) Capsules For Oral Use,2018-09-24 14:41:00-04:00,VSTM,positive
1330109.0,"Verastem Shares Halted, News Pending",2018-09-24 14:38:00-04:00,VSTM,positive
1330110.0,Verastem Reports Investigator-Sponsored Study On Duvelisib In Combo With Venetoclax,2018-09-06 07:04:00-04:00,VSTM,neutral
1330111.0,Court Filing Shows A US Judge Has Blocked State Of Texas's Fetal Tissue Burial Law,2018-09-05 15:08:00-04:00,VSTM,negative
1330112.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,VSTM,neutral
1330113.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,VSTM,neutral
1330114.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,VSTM,neutral
1330115.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,VSTM,positive
1330116.0,"The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration",2018-08-30 08:02:00-04:00,VSTM,neutral
1330117.0,Verastem Oncology Names Robert Gagnon CFO,2018-08-29 16:12:00-04:00,VSTM,neutral
1330118.0,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",2018-08-28 08:13:00-04:00,VSTM,neutral
1330119.0,"Stocks Which Set New 52-Week High Friday, August 24th",2018-08-27 09:24:00-04:00,VSTM,neutral
1330120.0,"Stocks Which Set New 52-Week High Yesterday, August 23rd",2018-08-24 09:11:00-04:00,VSTM,neutral
1330121.0,"Stocks Which Set New 52-Week High Yesterday, August 22nd",2018-08-23 10:51:00-04:00,VSTM,neutral
1330122.0,"Stocks Which Set New 52-Week High Yesterday, August 9th",2018-08-10 10:03:00-04:00,VSTM,neutral
1330123.0,Versatem shares are trading 15% higher on high volume after the company reported strong quarterly financial results.,2018-08-09 11:48:00-04:00,VSTM,positive
1330124.0,"Verastem Q2 EPS $(0.30) Beats $(0.34) Estimate, Sales $10M May Not Compare To $1.35M Estimate",2018-08-08 16:10:00-04:00,VSTM,neutral
1330125.0,Verastem S-3 Shows Registration For $200M Mixed Securities Shelf Offering,2018-07-24 16:42:00-04:00,VSTM,positive
1330126.0,38 Biggest Movers From Friday,2018-07-16 04:47:00-04:00,VSTM,neutral
1330127.0,30 Stocks Moving In Friday's Mid-Day Session,2018-07-13 12:38:00-04:00,VSTM,neutral
1330128.0,"Benzinga's Top Upgrades, Downgrades For July 13, 2018",2018-07-13 09:05:00-04:00,VSTM,positive
1330129.0,"BTIG Research Initiates Coverage On Verastem with Buy Rating, Announces $17 Price Target",2018-07-13 08:15:00-04:00,VSTM,neutral
1330130.0,41 Biggest Movers From Yesterday,2018-07-11 04:38:00-04:00,VSTM,neutral
1330131.0,32 Stocks Moving In Tuesday's Mid-Day Session,2018-07-10 12:20:00-04:00,VSTM,neutral
1330132.0,A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year,2018-07-05 12:25:00-04:00,VSTM,neutral
1330133.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Jun. 19, 2018",2018-06-19 12:27:00-04:00,VSTM,positive
1330134.0,"Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares",2018-06-19 08:08:00-04:00,VSTM,positive
1330135.0,60 Biggest Movers From Yesterday,2018-06-19 04:02:00-04:00,VSTM,neutral
1330136.0,Veristem Shares Closed Up 30.9% After Co.'s Duvelisib Showed Robust Clinical Activity In CLL,2018-06-18 17:36:00-04:00,VSTM,positive
1330137.0,Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher,2018-06-18 14:38:00-04:00,VSTM,negative
1330138.0,42 Stocks Moving In Monday's Mid-Day Session,2018-06-18 12:28:00-04:00,VSTM,neutral
1330139.0,Mid-Day Market Update: Verastem Shares Climb On Duvelisib Data; ZIOPHARM Oncology Shares Slide,2018-06-18 12:16:00-04:00,VSTM,positive
1330140.0,Verastem Shares Hit Highest Level Since 2015 On Duvelisib Data,2018-06-18 11:09:00-04:00,VSTM,positive
1330141.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Mon., Jun. 18, 2018",2018-06-18 10:53:00-04:00,VSTM,positive
1330142.0,Veristem Shares Up 14.2% Premarket After Co.'s Duvelisib Showed Robust Clinical Activity In CLL,2018-06-18 09:28:00-04:00,VSTM,positive
1330143.0,26 Stocks Moving In Monday's Pre-Market Session,2018-06-18 08:23:00-04:00,VSTM,neutral
1330144.0,40 Biggest Movers From Friday,2018-06-18 04:17:00-04:00,VSTM,neutral
1330145.0,Mid-Afternoon Market Update: Crude Oil Down Over 3%; Canada Goose Shares Gain Following Strong Q4 Results,2018-06-15 14:32:00-04:00,VSTM,positive
1330146.0,30 Stocks Moving In Friday's Mid-Day Session,2018-06-15 12:23:00-04:00,VSTM,neutral
1330147.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,VSTM,neutral
1330148.0,25 Stocks Moving In Friday's Pre-Market Session,2018-06-15 08:16:00-04:00,VSTM,neutral
1330149.0,"7 Stocks To Watch For June 15, 2018",2018-06-15 04:51:00-04:00,VSTM,neutral
1330150.0,7 Stocks Moving In Thursday's After-Hours Session,2018-06-14 17:06:00-04:00,VSTM,neutral
1330151.0,"UPDATE: Verastem Offering Prices 7,166,666 Shares Common Stock at $6/Share",2018-06-14 16:04:00-04:00,VSTM,positive
1330152.0,Verastem Oncology Announces $43M Common Stock Offering,2018-06-14 16:03:00-04:00,VSTM,neutral
1330153.0,"Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study",2018-06-07 07:58:00-04:00,VSTM,neutral
1330154.0,40 Biggest Movers From Yesterday,2018-06-07 04:50:00-04:00,VSTM,neutral
1330155.0,Hearing Agora Financial's Ray Blanco Of Breakthrough Technology Alert Is Out Positive On Verastem With A $15 Price Target,2018-06-06 12:16:00-04:00,VSTM,positive
1330156.0,45 Biggest Movers From Yesterday,2018-06-06 04:35:00-04:00,VSTM,neutral
1330157.0,35 Stocks Moving In Tuesday's Mid-Day Session,2018-06-05 12:25:00-04:00,VSTM,neutral
1330158.0,Benzinga Pro's 5 Stocks To Watch Today,2018-06-05 09:14:00-04:00,VSTM,neutral
1330159.0,30 Stocks Moving In Tuesday's Pre-Market Session,2018-06-05 08:06:00-04:00,VSTM,neutral
1330160.0,"Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index",2018-06-05 08:05:00-04:00,VSTM,positive
1330161.0,"Verastem Oncology, Yakult Honsha Co., Ltd. Sign Exclusive License Agreement for the Development and Commercialization of Duvelisib in Japan; Verastem to Receive $10M Upfront Payment; Up to Additional $90M for Milestones",2018-06-05 04:58:00-04:00,VSTM,positive
1330162.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,VSTM,negative
1330163.0,Verastem 8-K Shows News CFO Julie Feder Resigned; COO Daniel Paterson Named Principal Financial Officer On Interim Basis,2018-06-01 08:29:00-04:00,VSTM,negative
1330164.0,"Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended",2018-05-25 09:19:00-04:00,VSTM,negative
1330165.0,41 Biggest Movers From Yesterday,2018-05-17 04:32:00-04:00,VSTM,neutral
1330166.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-05-16 12:39:00-04:00,VSTM,neutral
1330167.0,"Verastem Oncology Prices 7.77M Shares At $4.50/Share, Gross Proceeds From The Offering Are Expected To Be $35M",2018-05-16 09:29:00-04:00,VSTM,negative
1330168.0,Verastem Shares Down 13.6% After Co. Late Tuesday Announced $35M Common Stock Offering,2018-05-16 09:03:00-04:00,VSTM,positive
1330169.0,26 Stocks Moving In Wednesday's Pre-Market Session,2018-05-16 08:14:00-04:00,VSTM,neutral
1330170.0,"Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings",2018-05-16 08:10:00-04:00,VSTM,neutral
1330171.0,"A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Housing Starts, Industrial Production Data",2018-05-16 07:38:00-04:00,VSTM,neutral
1330172.0,"8 Stocks To Watch For May 16, 2018",2018-05-16 05:59:00-04:00,VSTM,neutral
1330173.0,7 Stocks Moving In Tuesday's After-Hours Session,2018-05-15 17:14:00-04:00,VSTM,neutral
1330175.0,50 Biggest Movers From Friday,2018-05-14 05:07:00-04:00,VSTM,neutral
1330176.0,Verastem Q1 EPS $(0.41) Misses $(0.39) Estimate,2018-05-03 17:29:00-04:00,VSTM,negative
1330177.0,"Seaport Global Initiates Coverage On Verastem with Buy Rating, Announces $14 Price Target",2018-05-02 11:04:00-04:00,VSTM,neutral
1330178.0,40 Biggest Movers From Yesterday,2018-04-10 04:21:00-04:00,VSTM,neutral
1330179.0,Verastem Shares Up 10.8% After FDA Earlier Accepted New Drug Application For Duvelisib And Granted Priority Review,2018-04-09 15:52:00-04:00,VSTM,positive
1330180.0,31 Stocks Moving In Monday's Mid-Day Session,2018-04-09 12:32:00-04:00,VSTM,neutral
1330181.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-09 08:44:00-04:00,VSTM,neutral
1330182.0,20 Stocks Moving In Monday's Pre-Market Session,2018-04-09 08:06:00-04:00,VSTM,neutral
1330183.0,Verastem Announces FDA Accepts New Drug Application for Duvelisib and Grants Priority Review,2018-04-09 03:52:00-04:00,VSTM,positive
1330184.0,"Verastem Reports FY EPS $(1.76) vs $(1.74) Est., No Sales",2018-03-13 07:17:00-04:00,VSTM,negative
1330185.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-03-08 08:06:00-05:00,VSTM,neutral
1330186.0,33 Stocks Moving In Wednesday's Mid-Day Session,2018-02-07 12:16:00-05:00,VSTM,neutral
1330187.0,Benzinga Pro's 5 Stocks To Watch Today,2018-02-07 08:30:00-05:00,VSTM,neutral
1330188.0,20 Stocks Moving In Wednesday's Pre-Market Session,2018-02-07 08:14:00-05:00,VSTM,neutral
1330189.0,Verastem Submits New Drug Application to U.S. FDA for Duvelisib,2018-02-07 07:01:00-05:00,VSTM,neutral
1330190.0,28 Stocks Moving In Tuesday's Pre-Market Session,2018-01-30 08:00:00-05:00,VSTM,neutral
1330191.0,UPDATE: Verastem Says 'data support further exploration of duvelisib in combination with immunotherapeutic agents for the treatment of aggressive lymphomas',2018-01-26 14:50:00-05:00,VSTM,positive
1330192.0,Verastem Shares Spike Slightly Higher As Co. Issues Release Highlighting Preclinical Data At ASCO-SITC For Duvelisib In Combo With Immune Checkpoint,2018-01-26 14:48:00-05:00,VSTM,positive
1330193.0,"Verastem Files For 8,422,877 Shares Common Stock Offering, BTIG to Purchase The Shares At $2.97/Share",2017-12-18 16:24:00-05:00,VSTM,positive
1330194.0,33 Biggest Movers From Friday,2017-12-18 05:45:00-05:00,VSTM,neutral
1330195.0,Mid-Afternoon Market Update: Dow Surges Over 150 Points; Longfin Shares Spike Higher,2017-12-15 14:33:00-05:00,VSTM,positive
1330196.0,30 Stocks Moving In Friday's Mid-Day Session,2017-12-15 12:30:00-05:00,VSTM,neutral
1330197.0,Mid-Day Market Update: ShiftPixy Gains Following Q4 Results; Verastem Shares Plummet,2017-12-15 12:19:00-05:00,VSTM,positive
1330198.0,Mid-Morning Market Update: Markets Open Higher; Adobe Earnings Top Expectations,2017-12-15 10:11:00-05:00,VSTM,positive
1330199.0,Verastem Prices $25M Common Stock Offering,2017-12-15 09:19:00-05:00,VSTM,neutral
1330200.0,25 Stocks Moving In Friday's Pre-Market Session,2017-12-15 08:27:00-05:00,VSTM,neutral
1330201.0,Verastem Announces $25M Common Stock Offering,2017-12-14 17:07:00-05:00,VSTM,neutral
1330202.0,30 Stocks Moving In Tuesday's Pre-Market Session,2017-12-12 08:09:00-05:00,VSTM,neutral
1330203.0,42 Biggest Movers From Yesterday,2017-12-12 05:56:00-05:00,VSTM,neutral
1330204.0,"Verastem Announces Phase 1 Duvelisib Data From ASH, Demonstrates Acceptable Safety Profile",2017-12-11 17:01:00-05:00,VSTM,positive
1330205.0,30 Stocks Moving In Monday's Mid-Day Session,2017-12-11 12:07:00-05:00,VSTM,neutral
1330206.0,22 Stocks Moving In Monday's Pre-Market Session,2017-12-11 08:15:00-05:00,VSTM,neutral
1330207.0,36 Biggest Movers From Friday,2017-12-11 06:02:00-05:00,VSTM,neutral
1330208.0,Verastem Announces Clinical Data from the Pivotal Phase 3 DUO Study Showing Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory CLL Leukemia and SLL at #ASH2017,2017-12-10 17:37:00-05:00,VSTM,positive
1330209.0,25 Stocks Moving In Friday's Mid-Day Session,2017-12-08 12:01:00-05:00,VSTM,neutral
1330210.0,23 Stocks Moving In Friday's Pre-Market Session,2017-12-08 08:12:00-05:00,VSTM,neutral
1330211.0,38 Biggest Movers From Yesterday,2017-12-01 04:44:00-05:00,VSTM,neutral
1330212.0,Verastem Shares Up 12.84% On ~4x Avg. Volume; Hearing Roth Capital Earlier Initiated The Stock With Buy Rating And Price Target Of $12,2017-11-30 13:04:00-05:00,VSTM,positive
1330213.0,30 Stocks Moving In Thursday's Mid-Day Session,2017-11-30 12:49:00-05:00,VSTM,neutral
1330214.0,"Stifel 2017 Healthcare Conference Begins Today, Presenters Include: Seres Therapeutics, Verastem, TherapeuticsMD, Aerie Pharmaceuticals, Mednax, Celgene, TransEnterix, Exelixis, Tandem Diabetes Care and Masimo",2017-11-14 09:36:00-05:00,VSTM,positive
1330215.0,Verastem Reports Q3 EPS $(0.61) vs $(0.32) Est.,2017-11-07 07:29:00-05:00,VSTM,neutral
1330216.0,UPDATE: Verastem Reports Will Submit NDA For Duvelisib During Q1'18,2017-10-31 07:55:00-04:00,VSTM,neutral
1330217.0,Verastem Reports Regulatory Strategy For Duvelisib NDA: 'Plans to Submit a Single NDA Requesting Full Approval of Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma',2017-10-31 07:55:00-04:00,VSTM,positive
1330218.0,13 Stocks Moving In Wednesday's After-Hours Session,2017-10-18 17:38:00-04:00,VSTM,neutral
1330219.0,Verastem Announces a $6M Milestone Payment to Infinity Pharma,2017-10-17 07:14:00-04:00,VSTM,neutral
1330220.0,Verastem Names NgocDiep Le CMO,2017-10-11 16:20:00-04:00,VSTM,neutral
1330221.0,"Cantor Fitzgerald Global Healthcare Conference Begins Today, Presenters Include: Verastem, Advaxis, Exelixis, Heron Therapeutics, and Enanta Pharma",2017-09-25 09:30:00-04:00,VSTM,neutral
1330222.0,18 Stocks Moving In Monday's Pre-Market Session,2017-09-11 08:27:00-04:00,VSTM,neutral
1330223.0,25 Stocks Moving In Friday's Pre-Market Session,2017-09-08 08:05:00-04:00,VSTM,neutral
1330224.0,Mid-Afternoon Market Update: Crude Oil Up Over 1%; Sarepta Shares Jump After Positive Results In DMD Treatment Study,2017-09-06 14:30:00-04:00,VSTM,positive
1330225.0,Verastem Boosted After Positive Top-Line Data For Leukemia Treatment,2017-09-06 13:18:00-04:00,VSTM,positive
1330226.0,15 Biggest Mid-Day Gainers For Wednesday,2017-09-06 12:43:00-04:00,VSTM,neutral
1330227.0,Mid-Day Market Update: Trivago Drops On Weak Outlook; Verastem Shares Surge,2017-09-06 12:25:00-04:00,VSTM,negative
1330228.0,Mid-Morning Market Update: Markets Open Higher; G-III Apparel Tops Q2 Views,2017-09-06 10:11:00-04:00,VSTM,positive
1330229.0,Cantor Fitzgerald Upgrades Verastem to Overweight,2017-09-06 09:16:00-04:00,VSTM,negative
1330230.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-09-06 08:06:00-04:00,VSTM,neutral
1330231.0,Verastem's Phase 3 DUO Study Showed Statistically Significant Improvement,2017-09-06 06:13:00-04:00,VSTM,positive
1330232.0,Verastem's Duvelisib Receives Fast Track Designation from the FDA,2017-09-06 06:07:00-04:00,VSTM,neutral
1330233.0,Verastem Reports Q2 Loss/Share $(0.36) vs. $(0.34) Est.,2017-08-08 16:09:00-04:00,VSTM,neutral
1330234.0,"Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock",2017-07-17 12:52:00-04:00,VSTM,positive
1330235.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-07-13 08:04:00-04:00,VSTM,neutral
1330236.0,Verastem Appoints Julie Feder CFO,2017-07-11 16:06:00-04:00,VSTM,neutral
1330237.0,Verastem Spikes to High of  $4.47 on Volume,2017-07-11 13:32:00-04:00,VSTM,neutral
1330238.0,12 Biggest Mid-Day Gainers For Friday,2017-07-07 12:30:00-04:00,VSTM,neutral
1330239.0,20 Stocks Moving In Friday's Pre-Market Session,2017-07-07 08:12:00-04:00,VSTM,neutral
1330240.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-06-08 08:07:00-04:00,VSTM,neutral
1330241.0,"Verastem Offers Long-Term Follow-Up Data From DYNAMO Study: Showed '47% ORR in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma,' '88% of Patients had a Reduction in the Size of Target Lymph Nodes'",2017-06-07 16:08:00-04:00,VSTM,neutral
1330242.0,"Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data",2017-06-05 13:48:00-04:00,VSTM,neutral
1330243.0,Verastem Shares Volatile Over Last Few Mins as Traders Circulating Word of Positive Mention from Microcap Newsletter on Agora,2017-05-24 12:24:00-04:00,VSTM,positive
1330244.0,"Verastem Director Timothy J  Barberich Buys 30,000 Shares @ Avg Price: $2.45 -Form4",2017-05-17 08:34:00-04:00,VSTM,positive
1330245.0,Verastem Reports Q1 EPS $(0.35) vs $(0.35) Est.,2017-05-10 16:46:00-04:00,VSTM,neutral
1330246.0,"Oppenheimer Initiates Coverage On Verastem with Outperform Rating, Announces $6.00 Price Target",2017-04-13 09:11:00-04:00,VSTM,neutral
1330247.0,Hearing Oppenheimer Initiates On Verastem With Buy Rating and $6 PT,2017-04-12 16:19:00-04:00,VSTM,neutral
1330248.0,Verastem Announces Data on Focal Adhesion Kinase Inhibitor Defactinib Presented at AACR 2017,2017-04-02 19:39:00-04:00,VSTM,negative
1330249.0,15 Biggest Mid-Day Losers For Friday,2017-03-31 12:41:00-04:00,VSTM,negative
1330250.0,Verastem Files For $150M Mixed Shelf Offering,2017-03-30 17:28:00-04:00,VSTM,neutral
1330251.0,"H.C. Wainwright Reiterates Buy On Verastem, Raises Price Target To $6.50",2017-03-24 07:06:00-04:00,VSTM,neutral
1330252.0,Verastem Reports FY16 EPS $(0.99) vs $(1.18) Est.,2017-03-23 16:17:00-04:00,VSTM,neutral
1330253.0,Verastem Reports FY16 EPS $(0.99) vs. $(1.61) YoY,2017-03-23 16:02:00-04:00,VSTM,neutral
1330254.0,"Earnings Scheduled For March 23, 2017",2017-03-23 04:20:00-04:00,VSTM,neutral
1330255.0,18 Biggest Mid-Day Gainers For Monday,2017-03-13 12:51:00-04:00,VSTM,neutral
1330256.0,"Several Biotherapeutics Stocks Outperforming: Cerulean Pharma Up 44%, Adaptimmune 16%, Aurinia 15%, Versatem 14.5%, Heat Biologics 14%, Calithera 14%",2017-03-13 10:54:00-04:00,VSTM,neutral
1330257.0,Verastem Reports Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer,2017-01-26 07:13:00-05:00,VSTM,negative
1330258.0,"Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors",2017-01-19 12:29:00-05:00,VSTM,positive
1330259.0,Verastem Presents Phase 2 DYNAMO Clinical Data at ASH 2016,2016-12-06 05:59:00-05:00,VSTM,neutral
1330260.0,Verastem Reports Q3 Loss/Share $0.21 vs Est Loss/Share $0.24,2016-11-07 17:08:00-05:00,VSTM,neutral
1330261.0,Verastem Licenses Duvelisib from Infinity Pharmaceuticals,2016-11-02 06:52:00-04:00,VSTM,neutral
1330262.0,"Verastem Sees Having Sufficient Cash, Cash Equivalents, Short-Term Investments to Fund R&D Programs, Operations Into '18",2016-08-08 08:41:00-04:00,VSTM,neutral
1330263.0,Verastem Reports Q2 EPS $(0.23) vs $(0.29) Est.,2016-08-08 08:40:00-04:00,VSTM,neutral
1330264.0,Verastem Reports Q1 EPS $(0.22) vs $(0.30) Est.,2016-05-09 17:10:00-04:00,VSTM,neutral
1330265.0,Verastem Names Dr. Gregory Berk Chief Medical Officer,2016-04-18 17:20:00-04:00,VSTM,neutral
1330266.0,Verastem Reports Presentation of Data Supporting FAK Inhibition in Combo with Immunotherapy at Keystone Symposium on Cancer Pathophysiology,2016-03-30 16:07:00-04:00,VSTM,negative
1330267.0,Verastem to Present Scientific Data Supporting FAK and PI3K/mTOR Inhibition to Target Cancer Stem Cells at the Keystone Symposium on Stem Cells and Cancer,2016-03-10 07:00:00-05:00,VSTM,negative
1330268.0,Mid-Morning Market Update: Markets Open Lower; Joy Global Reports Wider-Than-Expected Q1 Loss,2016-03-03 10:06:00-05:00,VSTM,positive
1330269.0,"UPDATE: Merck, Pfizer, and Verastem Combination Trial Of Avelumab and VS-6063 Expected To Begin In 2nd Half 2016",2016-03-03 07:16:00-05:00,VSTM,neutral
1330270.0,Verastem Reports FY15 EPS $(1.61) vs. Prior Year Quarter $(2.07),2016-03-03 07:12:00-05:00,VSTM,neutral
1330271.0,"Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Report Combination Trial of Avelumab and VS-6063 in Ovarian Cancer",2016-03-03 07:10:00-05:00,VSTM,negative
1330272.0,Washington University Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer,2016-01-06 07:53:00-05:00,VSTM,negative
1330273.0,Verastem Reports Q3 EPS ($0.42) vs Est ($0.44),2015-11-09 07:04:00-05:00,VSTM,neutral
1330274.0,Verastem Reports Q3 EPS $(0.42) vs $(0.44) Est.,2015-11-09 07:03:00-05:00,VSTM,neutral
1330275.0,Verastem Reports Reduction Of Workforce By 50% To 20 Full Time Employees,2015-10-08 16:47:00-04:00,VSTM,neutral
1330276.0,Verastem Due Diligence: Cancels Phase II Study and Market Reacts - BrokerBank Securities,2015-09-30 08:05:00-04:00,VSTM,positive
1330277.0,Benzinga's Top Downgrades,2015-09-29 09:32:00-04:00,VSTM,positive
1330278.0,"UBS Downgrades Verastem to Neutral, Lowers PT to $16.00",2015-09-29 07:04:00-04:00,VSTM,negative
1330279.0,Jefferies Downgrades Verastem to Hold,2015-09-29 06:56:00-04:00,VSTM,neutral
1330280.0,"Mizuho Securities Downgrades Verastem to Neutral, Lowers PT to $2.00",2015-09-28 14:03:00-04:00,VSTM,positive
1330281.0,Morning Market Losers,2015-09-28 09:59:00-04:00,VSTM,negative
1330282.0,Roth Capital Downgrades Verastem to Neutral,2015-09-28 09:44:00-04:00,VSTM,neutral
1330283.0,Benzinga's Top #PreMarket Losers,2015-09-28 08:25:00-04:00,VSTM,negative
1330284.0,"Shares of Verastem Trading Down to $2.99, Down ~47% from Friday's Close",2015-09-28 07:45:00-04:00,VSTM,positive
1330285.0,"Shares of Verastem Resume Trade, Now Down to $4.27",2015-09-28 07:30:00-04:00,VSTM,positive
1330286.0,Shares of Verastem to Resume Trade at 7:30 a.m. EDT,2015-09-28 07:07:00-04:00,VSTM,positive
1330287.0,Verastem Reports Stopping Enrollment in COMMAND Study of VS-6063,2015-09-28 07:00:00-04:00,VSTM,negative
1330288.0,Verastem Shares Halted News Pending,2015-09-28 06:56:00-04:00,VSTM,positive
1330289.0,Verastem Reports New Research Published in Journal Cell Related to Potential of FAK Inhibition for Enhancement of Efficacy of Anti-Tumor Immunotherapy,2015-09-24 16:01:00-04:00,VSTM,negative
1330290.0,"Roth's Pantginis Comments on Verastem: 'After Abstract Debacle, '6063 Data Impress in NSCLC,' Buy Rating, $23 Price Target Reiterated",2015-09-10 13:48:00-04:00,VSTM,positive
1330291.0,Stocks Hitting 52-Week Lows,2015-08-26 10:10:00-04:00,VSTM,negative
1330292.0,Morning Market Losers,2015-08-26 09:52:00-04:00,VSTM,negative
1330293.0,Benzinga's Top #PreMarket Losers,2015-08-26 08:27:00-04:00,VSTM,negative
1330294.0,10 Biotech Stocks With Catalysts Coming Soon,2015-08-20 12:19:00-04:00,VSTM,neutral
1330295.0,Verastem Reports Q2 Loss $0.42 vs Est Loss $0.45,2015-08-10 07:05:00-04:00,VSTM,negative
1330296.0,Verastem Announces Chief Medial Officer to Move to Advisory Role,2015-06-10 07:02:00-04:00,VSTM,neutral
1330297.0,Oppenheimer Assumes Verastem at Perform,2015-04-27 07:55:00-04:00,VSTM,neutral
1330298.0,Verastem Presents Encouraging Scientific Data on Preferential Targeting of Cancer Stem Cells at AACR,2015-04-22 07:03:00-04:00,VSTM,negative
1330299.0,"H.C. Wainwright Initiates Coverage on Verastem at Buy, Announces $16.00 PT",2015-04-08 07:26:00-04:00,VSTM,neutral
1330300.0,"Bind Therapeutics Inc, Noble Energy, Inc., Others Are Moving After-Hours",2015-04-02 21:21:00-04:00,VSTM,positive
1330301.0,Verastem Reports FY14 Loss of $2.07/Share vs Loss of $2.08/Share Est.; Says Command Enrollment Remains On Track,2015-03-10 07:15:00-04:00,VSTM,negative
1330302.0,"Novartis, Verastem & Cepheid Making Biotech Headlines On Friday",2015-02-13 15:32:00-05:00,VSTM,neutral
1330303.0,Verastem Receives FDA Orphan Designation for Defactinib for Ovarian Cancer,2015-02-13 11:03:00-05:00,VSTM,negative
1330304.0,3 Biotech IPOs Debuting This Week,2015-01-26 15:14:00-05:00,VSTM,neutral
1330305.0,Verastem Prices 7.25M Share Offering @$6.50/Share,2015-01-22 20:44:00-05:00,VSTM,positive
1330306.0,5 Biotech Secondaries Traders Are Watching,2015-01-21 13:32:00-05:00,VSTM,neutral
1330307.0,Verastem Announces $40M Proposed Public Offering of Common Stock,2015-01-20 16:01:00-05:00,VSTM,neutral
1330308.0,Verastem Doses First Patient in Phase 1 Clinical Trial Evaluating VS-5584 in Combination with VS-6063 in Mesothelioma,2015-01-20 08:04:00-05:00,VSTM,neutral
1330309.0,US Stock Futures Surge Ahead Of Earnings,2015-01-20 07:16:00-05:00,VSTM,neutral
1330310.0,Verastem Doses First Patient in Phase 1 Clinical Trial Evaluating VS-5584 in Combination with VS-6063 in Mesothelioma,2015-01-20 07:05:00-05:00,VSTM,neutral
1330311.0,What Investors Are Looking At In The Stem Cell Sector,2015-01-13 11:48:00-05:00,VSTM,neutral
1330312.0,"Verastem Director Termeer Buys 19,100 Shares @$8.09/Share -Form 4",2014-12-24 11:11:00-05:00,VSTM,positive
1330313.0,"Verastem COO Paterson Buys 2,000 Shares @$8.52/Share -Form 4",2014-12-22 10:36:00-05:00,VSTM,positive
1330314.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,VSTM,neutral
1330315.0,"Verastem Director Lawton Buys 2,500 Shares @$9.17/Share -Form 4",2014-11-12 15:01:00-05:00,VSTM,positive
1330316.0,Verastem To Participate In Panel At The MassBio Patient Advocacy Summit,2014-11-10 07:02:00-05:00,VSTM,neutral
1330317.0,"Verastem, Inc. Reports Q3 EPS of $(0.52), Inline",2014-10-30 07:06:00-04:00,VSTM,neutral
1330318.0,Verastem Reports Q2 EPS -$0.51 vs -$0.51 Est. Does Not Compare,2014-08-07 16:18:00-04:00,VSTM,neutral
1330319.0,"Oppenheimer Initiates Coverage on Verastem, Inc. at Market Perform, Announces $8.99 PT",2014-07-08 06:23:00-04:00,VSTM,neutral
1330320.0,"Verastem Presents Updated Clinical Data from VS-6063, Paclitaxel Combination Phase 1/1b Study in Patients with Ovarian Cancer at ASCO",2014-06-02 07:06:00-04:00,VSTM,negative
1330321.0,"Verastem, Inc. Reports Q1 EPS of $(0.51) vs $(0.43) Est",2014-05-08 16:52:00-04:00,VSTM,neutral
1330322.0,UPDATE: Deutsche Bank Initiates Coverage On Verastem On Multiple Positive Factors,2014-05-06 09:10:00-04:00,VSTM,positive
1330323.0,"Deutsche Bank Initiates Coverage on Verastem, Inc. at Buy, Announces $14.00 PT",2014-05-06 08:06:00-04:00,VSTM,neutral
1330324.0,"Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients; Completes Full Enrollment and was ""Well Tolerated"" at Each Dosage Level",2014-03-05 16:04:00-05:00,VSTM,positive
1330325.0,Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718,2014-02-25 07:07:00-05:00,VSTM,negative
1330326.0,Verastem Issued Japanese Patent for Dual mTORC1/2 and PI3K Inhibitor VS-5584 ,2014-02-04 07:06:00-05:00,VSTM,negative
1330327.0,Verastem Initiates Phase 1 Trial of Dual mTOR/PI3K Inhibitor ,2013-12-10 07:16:00-05:00,VSTM,negative
1330328.0,Verastem Begins Phase 2 Trial of Defatinib in Lunc Cancer,2013-09-26 09:37:00-04:00,VSTM,negative
1330329.0,Verastem Initiates Defactinib Trial in Japan ,2013-09-24 07:03:00-04:00,VSTM,neutral
1330330.0,Verastem Issued U.S. Patent Covering VS-4718 Composition of Matter ,2013-08-15 07:00:00-04:00,VSTM,neutral
1330331.0,"Verastem, Inc. Reports Q2 EPS of $(0.49) vs $(0.41) Est",2013-08-13 07:01:00-04:00,VSTM,neutral
1330332.0,"Earnings Scheduled For August 13, 2013",2013-08-13 05:58:00-04:00,VSTM,neutral
1330333.0,UPDATE: Jefferies Initiates Verastem at Buy on Cancer Research Potential,2013-07-29 09:22:00-04:00,VSTM,negative
1330334.0,Benzinga's Top Initiations,2013-07-29 08:42:00-04:00,VSTM,positive
1330335.0,"Jefferies Initiates Coverage on Verastem, Inc. at Buy, Announces $21.00 PT",2013-07-29 07:53:00-04:00,VSTM,neutral
1330336.0,"Jefferies Initiates Coverage on Verastem, Inc. at Buy, Announces $21.00 PT",2013-07-29 07:48:00-04:00,VSTM,neutral
1330337.0,Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma,2013-07-24 07:07:00-04:00,VSTM,neutral
1330338.0,Verastem Drug Achieves a Complete Response in Platinum-Resistant Ovarian Cancer ,2013-07-23 07:15:00-04:00,VSTM,negative
1330339.0,Verastem Says CRL Confirmed in VS-6063 Trial,2013-07-23 07:08:00-04:00,VSTM,neutral
1330340.0,"Market Wrap for Wednesday, July 17: Stocks Rise as Bernanke Emphasizes Flexibility of Stimulus Program",2013-07-17 16:23:00-04:00,VSTM,positive
1330341.0,Verastem Announces Pricing of Public Offering of Common Stock At $15,2013-07-17 09:24:00-04:00,VSTM,neutral
1330342.0,Verastem Announces Proposed Public Offering of Common Stock ,2013-07-16 16:08:00-04:00,VSTM,neutral
1330343.0,UPDATE: Oppenheimer Raised PT on Verastem Following Analyst Day,2013-07-12 08:31:00-04:00,VSTM,neutral
1330344.0,Verastem Presents Results and Updated Development Plans ,2013-07-11 16:58:00-04:00,VSTM,neutral
1330345.0,Benzinga's Volume Movers,2013-07-09 11:08:00-04:00,VSTM,neutral
1330346.0,Benzinga's Top Initiations,2013-07-09 08:40:00-04:00,VSTM,positive
1330347.0,UPDATE: Cantor Fitzgerald Initiates Verastem at Buy on Compelling Mix of Catalysts,2013-07-09 08:31:00-04:00,VSTM,positive
1330348.0,"Cantor Fitzgerald Initiates Coverage on Verastem, Inc. at Buy, Announces $22.00 PT",2013-07-08 16:17:00-04:00,VSTM,neutral
1330349.0,Verastem Successfully Completes Phase 1 Stage of Combination Trial of Cancer Stem Cell Inhibitor VS-6063 and Paclitaxel ,2013-06-27 07:05:00-04:00,VSTM,negative
1330350.0,Verastem Initiates Phase 1 Clinical Trial of VS-4718 in Patients with Advanced Cancer ,2013-06-26 07:08:00-04:00,VSTM,negative
1330351.0,"Market Wrap for Thursday, June 13: Strong Economic Reports Trigger Stock Rally ",2013-06-13 16:24:00-04:00,VSTM,positive
1330352.0,Afternoon Market Gainers ,2013-06-13 13:06:00-04:00,VSTM,neutral
1330353.0,Verastem Wins Orphan Medicinal Product Designation from EC for VS-6063,2013-06-13 07:05:00-04:00,VSTM,positive
1330354.0,Verastem Appoints Robert Forrester as Chief Executive Officer ,2013-06-06 08:00:00-04:00,VSTM,neutral
1330355.0,Jack Green Named Verastem CFO,2013-05-14 07:05:00-04:00,VSTM,neutral
1330356.0,"Earnings Scheduled For March 27, 2013",2013-03-27 04:47:00-04:00,VSTM,neutral
1330357.0,"Roth Capital Initiates Coverage on Verastem, Inc. at Buy, Announces $18.00 PT",2013-03-13 09:20:00-04:00,VSTM,neutral
1330358.0,"Guggenheim Securities Initiates Coverage on Verastem, Inc. at Buy, Announces $16.00 PT",2013-02-22 09:17:00-05:00,VSTM,positive
1330359.0,Verastem Files for Orphan Disease Status in US and EU for VS-6063 in Mesothelioma ,2013-02-14 07:15:00-05:00,VSTM,neutral
1330360.0,"From Earlier: JMP Securities Initiates Coverage on Verastem, Inc. at Market Outperform, Announces $20.00 PT",2013-02-08 10:16:00-05:00,VSTM,positive
1330361.0,Verastem Announces Publication of Data for VS-5584 in Molecular Cancer Therapeutics,2013-02-06 07:22:00-05:00,VSTM,negative
1330362.0,Verastem Enters Agreement with LabCorp to Validate Biomarkers ,2013-01-09 07:57:00-05:00,VSTM,positive
1330363.0,Verastem Reports Q3 EPS $-0.51 vs $-0.36 Est,2012-11-13 07:41:00-05:00,VSTM,neutral
1330364.0,Verastem Reports Q2 EPS $-0.34 vs $-0.34 Est,2012-08-13 07:27:00-04:00,VSTM,neutral
1330365.0,A Peek Into The Market Before The Trading Starts,2012-07-12 07:21:00-04:00,VSTM,neutral
1330366.0,Verastem Enters Research Collaboration with Eisai for Small Molecule Wnt Inhibitors   ,2012-07-12 07:01:00-04:00,VSTM,negative
1330367.0,Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer   ,2012-07-11 16:05:00-04:00,VSTM,negative
1330368.0,Verastem Announces Addition to Russell 2000 Index   ,2012-04-03 08:03:00-04:00,VSTM,neutral
1330369.0,Oppenheimer: Verastem Reports FY11 Results,2012-03-15 07:16:00-04:00,VSTM,neutral
1330370.0,UPDATE: Oppenheimer Initiates Verastem's Rating and PT,2012-03-07 08:02:00-05:00,VSTM,neutral
1330371.0,Longwood Reports 13.63% Stake in Verastem,2012-02-14 17:36:00-05:00,VSTM,neutral
1330372.0,From Earlier: Underwriters Exercise Over-Allotment Option for Verastem Initial Public Offering  ,2012-02-02 07:10:00-05:00,VSTM,neutral
1330373.0,Verastem IPO Launch Captures Investors Attention,2012-02-01 22:54:00-05:00,VSTM,neutral
1330374.0,Verastem raises $55 mn in IPO,2012-01-27 13:21:00-05:00,VSTM,neutral
1330375.0,"Verastem IPO Opens for Trading at $11.10, after Pricing at $10.00/Share",2012-01-27 10:40:00-05:00,VSTM,neutral
